Stock Ratings / Health Care / UFPT / forecast

INSP (65) XRAY (32) LMAT (67) KMTS (50) ⌘ Pro Terminal →

UFP Technologies Inc. (UFPT) 12-Month Stock Forecast & Price Target Cone

$284.50 -3.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $283.65

UFP Technologies Inc. (UFPT) earns a Roarable Rating of B (Buy) with 74/100 RQD Confidence. High-quality cash engine (28% profit margin, 14% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 74/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.3% avg 90D alpha vs SPY • 69.4% hit rate) →

ROARABLE B • BUY Cap $2.20B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on UFPT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is UFPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, UFP Technologies Inc. (NASDAQ: UFPT) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $284.50 (-3.00% 1D, market cap $2.20B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, UFPT ranks #43 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does UFPT compare to INSP and XRAY in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), UFPT carries a Roarable B (74/100 RQD), trailing P/E of 33.3x, gross margin of 28.3%, and ROIC of 13.9%. By comparison, INSP (Inspire Medical Systems Inc.) holds a C grade (65/100 RQD, P/E 14.2x, ROIC 6.0%, cap $1.97B) and XRAY (DENTSPLY SIRONA Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -11.0%, cap $1.90B). Among the 5-stock peer group, INSP leads on earnings multiple (14.2x) while LMAT leads on capital efficiency (14.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for UFPT?

▼

Per UFPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000914156), UFP Technologies Inc. generated $602.8M in revenue (+19.5% YoY), $68.3M in net income, and $91.9M in free cash flow against $655.1M in total assets and $123.0M in total debt. Key quantitative strengths: Strong cash generator (28% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $283.65 (-0.30%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 15.2% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 74/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.3% avg 90D alpha vs SPY • 69.4% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B- · Rk B+

Each axis scored 0–20

12M PRICE TARGET CONE+7.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for UFPT)Realized 20D OHLCV Swing Band: ±6.9%

Deterministic 5-Pillar Attribution (74/100 Composite)

🔍 WHY UFPT SCORES 74/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (24% of score)

Altman Z-Score 8.31 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▲ #2 Bullish Driver: Cash Engine Quality+17/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 15.2% FCF Margin ($91.9M FCF) & 28.3% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning10/20 pts (-10 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-10 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade A$294.29-1% Next Q

Q2 (-2Q)

Grade A-$291.34+1.2% Next Q

Q3 (-1Q)

Grade B+$294.84-3.5% Next Q

Current

Grade B$284.50+7.3% Hist 90D α

Trajectory: A (82) → B (74)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the UFPT Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 74/100 (B) score, UFPT faces multiple-compression risk if 33.3x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 25.8% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($291.00) or 200D SMA ($249.56) invalidates the momentum regime and cuts Target Base ($304.98) toward Bear Floor ($233.29).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $UFPT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “UFPT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 74%NO 26%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your UFPT Position Size: $10,000

Shares at $284.50: 35.1 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $233.29

$8,200

$-1,800 (-18.0%)

12M Consensus BaseTarget $304.98

$10,720

+$720 (+7.2%)

12M Bull Case BreakoutTarget $359.88

$12,650

+$2,650 (+26.5%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (34 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 23● Hold: 9● Sell: 2

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	OUTPERFORM	$317	74%	A
Goldman SachsSector Coverage Lead	STRONG BUY	$338	69%	B
JP MorganUS Large-Cap Research	HOLD	$269	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (UFPT Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

UFPT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +47.75%⚡ TESTING RESISTANCE

2026-11-03O $293.3H $293.3L $284.5C $284.5VOL 85.4K

RES: $297.2SUP: $281.1SMA50: $291.0SMA200: $249.6

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

UFPT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 UFPT Butterfly Map → + Track UFPT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

25.7%/yr Implied 5Y Growth

vs. +19.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on UFPT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for UFPT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for UFPT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (UFPT)

Health Care Rank #43 of 1016 ⚔️ INSP vs UFPT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (UFPT vs. INSP, XRAY, LMAT, KMTS)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, UFP Technologies Inc. (UFPT) ranks #43 by composite RQD confidence (74/100, grade B) and #241 by equity capitalization ($2.20B). Within this direct 5-issuer industry benchmark cohort, INSP leads on earnings valuation at 14.2x trailing P/E, while LMAT leads on capital efficiency and profitability with 14.7% ROIC and 71.5% gross margin. UFPT currently leads its immediate peer cohort in composite quantitative strength at 74/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
UFPT ACTIVE UFP Technologies Inc.	B	74/100	33.3x	28.3%	13.9%	-3.00%	$2.20B	Benchmark Subject
INSP Inspire Medical Systems Inc.	C	65/100	14.2x	85.4%	6.0%	-4.33%	$1.97B	/insp-vs-ufpt →
XRAY DENTSPLY SIRONA Inc.	E	32/100	—	50.0%	-11.0%	-0.83%	$1.90B	/xray-vs-ufpt →
LMAT LeMaitre Vascular Inc.	C+	67/100	33.8x	71.5%	14.7%	-5.08%	$1.85B	/lmat-vs-ufpt →
KMTS Kestra Medical Technologies Ltd.	D	50/100	—	51.4%	-35.0%	-3.01%	$1.77B	/kmts-vs-ufpt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000914156

In its most recent audited fiscal period (FY2025, filed 2025-12-31), UFP Technologies Inc. (UFPT) reported GAAP revenue of $602.8M (+19.5% vs. FY2024 revenue of $504.4M , and +50.7% cumulative change since FY2023) , GAAP net income of $68.3M, operating cash flow of $91.9M, and free cash flow of $91.9M (+61.4% YoY). On the balance sheet, UFPT closed FY2025 with $655.1M in total assets against $123.0M in total debt (Altman Z-Score: 8.31, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$602.8M	$68.3M	$91.9M	$91.9M	$655.1M	$123.0M
FY2024 (FY)	2024-12-31	$504.4M	$59.0M	$66.6M	$56.9M	$629.0M	$176.9M
FY2023 (FY)	2023-12-31	$400.1M	$44.9M	$41.3M	$41.3M	—	—

3. UFPT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is UFPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does UFPT compare to INSP and XRAY in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for UFPT?

Where is UFPT trading relative to its 50-day, 200-day, and 52-week technical levels?

UFPT last traded at $284.50 (-3.00% on volume of 85,423 shares), positioning the stock -2.23% below its 50-day simple moving average ($291.00) and +14.00% above its 200-day simple moving average ($249.56). Across its 52-week range of $173.86 to $338.71, UFPT sits at the 67.1% percentile with a 14-day RSI of 45.0 (NEUTRAL RANGE) and an implied next-earnings move of ±6.9% ($264.87 to $304.13).

UFPT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is UFPT's 12-month stock price target?

UFP Technologies Inc. (UFPT) carries a 12-month consensus base price target of $304.98 (+7.2% from $284.50), with a bull-case target of $359.88 and a bear-case floor of $233.29.

Is UFPT stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates UFPT B (Buy — BUY) with an RQD Confidence score of 74/100.

Direct Sub-Reports: UFPT RQD Cockpit UFPT 12M Forecast UFPT Earnings & Move UFPT Dividends & DRIP UFPT Insiders & 13F UFPT Whale Options UFPT Profit Sankey UFPT News & Why

Sector Peer Dials

Compare →

INSP C

Inspire Medical Systems Inc.

LeMaitre Vascular Inc.

67 /100

KMTS D

Kestra Medical Technologies Ltd.

UFPT Core Snapshot

Market Cap $2.20B

Trailing / Fwd P/E 33.3x / 28.0x

Gross Profit Margin 28.3%

Return on Capital (ROIC) 13.9%

Free Cash Flow Yield 4.05%

12M Base Price Target $304.98

FREE TRADER TOOLS

Own UFPT Alongside Other Stocks? Run a 30-Second Crash X-Ray

Drop 3–5 tickers into our live Portfolio X-Ray to spot hidden accounting time-bombs and see your composite RQD dial.

⚡ X-Ray My Portfolio With UFPT → 🏆 Trade UFPT in $100K Prop Arena →

UFPT Wire

Why It Moved →

Direct Company Event Yahoo Finance • 16h ago

2 Reasons to avoid UFPT and 1 stock to buy instead

Direct Company Event Seeking Alpha • 19h ago

UFP Technologies: Re-Rated As Organic Growth Returns (NASDAQ:UFPT)

Direct Company Event TradingView • 22h ago

UFP Technologies (UFPT) Q3 earnings report preview: what to look for

Direct Company Event Moomoo • 1d ago

Do UFP Technologies' (NASDAQ:UFPT) Earnings Warrant Your Attention?

Peer / Ecosystem Wire Stock Titan • 1d ago

A results call is set for Nov. 4 at 8:30 a.m.

ROARABLE RATING BRIEF • RQD 74/100 (B) ✓ STAGE-C NUMBER FIREWALL VERIFIED

UFPT — UFP Technologies Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:26:10Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, UFPT scores 77 out of 100, a B+ grade, labeled "Roarable Buy — Very Good Cash & Smart-Money Inflow." The five pillars are:

Fundamental Cash Engine: 17 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of 13.9% and an FCF yield of 4.05%. For a prospective investor, this indicates the business converts capital into returns at a healthy rate, though a 4.05% FCF yield means the stock is priced at a premium to its current cash generation.
Whale / 13F Flow: 13 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. The score is moderate, suggesting institutional interest is present but not dominant.
Insider Conviction: 15 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The score is solid, indicating insider and disclosed trading activity is net supportive, though the underlying trade-level detail is not provided in the source data.
Macro Regime Fit: 14 / 20. Per the Roarable RQD rating, this pillar reflects a beta of 1.0 and sector sensitivity. A beta of 1.0 means the stock is expected to move in line with the broader market, offering neither defensive insulation nor amplified volatility.
Forensic Balance Sheet: 18 / 20. Per the Roarable RQD rating, this pillar reflects an Altman Z-Score of 8.31, a Piotroski F-Score of 9/9, and a Debt/Equity ratio of 0.29. These are the strongest pillar readings and signal low distress risk and high financial quality.

Investor implications. The upside drivers are the cash engine and balance sheet strength. The valuation tradeoff is that the P/E (TTM) of 33.3 and EV/EBITDA of 25.7 are elevated relative to the FCF yield, so future returns depend on sustained earnings growth. This is an analytical framework, not personalized financial advice.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %
293.3	$2.27B	33.3	28	25.7	8.82	0%	1.0	$173.86 - $338.71	13.9%

Business

UFP Technologies Inc. (UFPT) is a NASDAQ-listed issuer in the Health Care sector and the Medical/Dental Instruments industry. Per the company profile, the company carries a market capitalization of $2.3B. Not available in source data for specific product lines, customer base, or revenue model detail.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$602.8M	$92.3M	$68.3M	N/A	$91.9M	$20.3M	$123.0M
FY 2024	$504.4M	$80.9M	$59.0M	N/A	$56.9M	$13.4M	$176.9M
FY 2023	$400.1M	$57.7M	$44.9M	N/A	$41.3M	N/A	N/A

Per the SEC financials, revenue rose from $400.1M (FY 2023) to $602.8M (FY 2025), and net income rose from $44.9M to $68.3M over the same span. Gross margin is 28.3%, operating margin 15.3%, and net margin 11.3%, per the market data. ROIC is 13.9%. Per the Roarable RQD rating, the Altman Z-Score is 8.31 and the Piotroski F-Score is 9/9. Debt fell from $176.9M (FY 2024) to $123.0M (FY 2025), and Debt/Equity is 0.29 per the RQD rating.

Recent Catalysts & News Wire Analysis

Green (Catalyst): Seeking Alpha headline "UFP Technologies: Re-Rated As Organic Growth Returns (NASDAQ:UFPT)" flags organic growth as a positive driver.
Yellow (Market Wire): Multiple neutral items, including a Yahoo Finance piece on avoiding UFPT, a TradingView Q3 earnings preview, a Moomoo earnings-warrant-attention piece, and a Stock Titan notice that a results call is set for Nov. 4 at 8:30 a.m.
Red (Risk Watch): MarketBeat reports that Congress Asset Management Co. cut its UFPT position.
Butterfly Supply-Chain Graph: Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals.

Open Questions

What is the company's product mix, end-market exposure, and customer concentration?
What were the reported EPS figures, since the financials list EPS as N/A for all periods?
What drove the cash and debt figures for FY 2023, which are listed as N/A?
What does the Q3 earnings release (scheduled Nov. 4 per the news wire) show against the organic-growth narrative?
What is the consensus analyst rating and price target, and what do 13F and insider trade records show in detail?

UFPT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for UFP Technologies Inc. (UFPT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to UFPT Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 16h ago

2 Reasons to avoid UFPT and 1 stock to buy instead

Yahoo Finance report covering UFP Technologies Inc. (UFPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Seeking Alpha • 19h ago

UFP Technologies: Re-Rated As Organic Growth Returns (NASDAQ:UFPT)

Seeking Alpha report covering UFP Technologies Inc. (UFPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 22h ago

UFP Technologies (UFPT) Q3 earnings report preview: what to look for

TradingView report covering UFP Technologies Inc. (UFPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 1d ago

Do UFP Technologies' (NASDAQ:UFPT) Earnings Warrant Your Attention?

Moomoo report covering UFP Technologies Inc. (UFPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A results call is set for Nov. 4 at 8:30 a.m.

Stock Titan report covering UFP Technologies Inc. (UFPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH MarketBeat • 1d ago

Congress Asset Management Co. Cuts Stock Position in UFP Technologies, Inc. $UFPT

MarketBeat report covering UFP Technologies Inc. (UFPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Is UFP Technologies (UFPT) Undervalued After Argus Lifted Its Price Target?

Simply Wall St report covering UFP Technologies Inc. (UFPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Q2 Earnings Roundup: UFP Technologies (NASDAQ:UFPT) And The Rest Of The Drug Development Inputs & Services Segment

TradingView report covering UFP Technologies Inc. (UFPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

UFPT Bull vs. Bear Conversation Board — What's Your Call at $284.50?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON UFPT 🐻 33% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $346.09 (+18.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is UFPT (B+ • RQD 77/100) a Buy at $293.30?

Welcome to the UFPT (UFP Technologies Inc.) Roar Pit. Current RQD Composite is 77/100 (Roarable Buy — Very Good Cash & Smart-Money Inflow) in Medical/Dental Instruments. Bulls point to capital efficiency (13.9% ROIC), while bears focus on valuation multiple compression (33.3x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $240.51 (-18.0%)

Spot @ $293.30

Pump the brakes on UFPT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on UFPT, but look at what you are paying: 33.3x trailing P/E with 28.3% gross margins. Unless UFP Technologies Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $354.89 (+21.0%)

Spot @ $293.30

UFPT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on UFPT, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $293.30 (52-wk range $173.86 - $338.71), any beat on forward guidance forces shorts and underweight funds to chase.